Efficacy and Safety of Sunitinib in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004363-74

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To confirm sunitinib treatment effect on progression-free survival (PFS) per investigator assessment in subjects with advanced/metastatic, well differentiated, unresectable, pancreatic neuroendocrine tumors per RECIST.


Critère d'inclusion

  • PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS